Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Acquisitions & Divestments (2023 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $107.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 139.32% to $107.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $251.0 million, a 26.35% increase, with the full-year FY2024 number at $171.8 million, up 24.45% from a year prior.
  • Change in Acquisitions & Divestments was $107.7 million for Q3 2025 at Centessa Pharmaceuticals, up from $43.2 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $107.7 million in Q3 2025 to a low of $25.0 million in Q4 2024.
  • A 3-year average of $59.5 million and a median of $51.8 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 51.76% in 2024, then soared 139.32% in 2025.
  • Centessa Pharmaceuticals' Change in Acquisitions & Divestments stood at $51.8 million in 2023, then crashed by 51.76% to $25.0 million in 2024, then skyrocketed by 330.76% to $107.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Acquisitions & Divestments are $107.7 million (Q3 2025), $43.2 million (Q2 2025), and $75.1 million (Q1 2025).